Management of patients with chronic lymphocytic leukemia treated with lenalidomide

Clinical Journal of Oncology Nursing

Volumn 14, Issue 4, 2010, Pages 491-499

  Miller, Kena C ^a   Musial, Laurie ^b   Whitworth, Amy ^b   Chanan Khan, Asher ^c  

^a Department of Medicine ^*  (United States)

^b West River Pharm   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; LENALIDOMIDE; THALIDOMIDE;

CHRONIC LYMPHATIC LEUKEMIA; DRUG ADMINISTRATION; DRUG MONITORING; HUMAN; NURSING; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; THALIDOMIDE;

EID: 79952108154     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/10.CJON.491-499     Document Type: Article

References (42)

1. Anaissie, E.J., Kontoyiannis, D.P., O'Brien, S., Kantarjian, H., Robertson, L., Lerner, S., & Keating, M.J. (1998). Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Annals of Internal Medicine, 129, 559-566.
2. Badoux, X., Reuben, J., Lee, B., Jorgensen, J., Estrov, Z., Yerrow, K.,. Ferrajoli, A. (2009). Lenalidomide therapy is associated with normalization of lymphocyte populations and increase in immunoglobulin levels in elderly patients with chronic lymphocytic leukemia [Abstract 10.31]. Haematologica, 94(3, Suppl.), S94.
3. Badoux, X., Wierda, W.G., O'Brien, S.M., Faderl, S., Estrov, Z., Yerrow, K., Ferrajoli, A. (2009). Experience with lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukaemia [Abstract 10.30]. Haematologica, 94(3, Suppl.), S93.
4. Byrd, J.C., Marcucci, G., Parthun, M.R., Xiao, J.J., Klisovic, R.B., Moran, M., Grever, M.R. (2005). A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 105, 959-967.
5. Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., Larson, R.A. (2003). Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia. Blood, 101, 6-14.
6. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J., Bezares, R.F., NCRI Chronic Lymphocytic Leukaemia Working Group. (2007). Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet, 370(9583), 230-239. doi: 10.1016/S0140-6736(07)61125-8
7. Celgene Corporation. (2009). Revlimid® (lenalidomide) [Prescribing information]. Retrieved from http://www.revlimid.com/pdf/REVLIMID_PI.pdf
8. Chanan-Khan, A., Miller, K.C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K.,. Czuczman, M.S. (2006). Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. Journal of Clinical Oncology, 24, 5343-5349. doi: 10.1200/JCO.2005.05.0401
9. Chanan-Khan, A.A., & Cheson, B.D. (2008). Lenalidomide for the treatment of B-cell malignancies. Journal of Clinical Oncology, 26, 1544-1552. doi: 10.1200/JCO.2007.14.5367
10. Chen, C., Paul, H., Xu, W., Kukreti, V., Trudel, S., Wei, E., Leung-Hagensteijn, C. (2008). A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL) [Abstract 44]. Blood, 112, 728.
11. Cheson, B.D. (2009). Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia. Clinical Advances in Hematology and Oncology, 7, 263-271.
12. Coiffier, B., Altman, A., Pui, C.H., Younes, A., & Cairo, M.S. (2008). Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. Journal of Clinical Oncology, 26, 2767-2778. doi: 10.1200/JCO.2007.15.0177
13. Corral, L.G., Muller, G.W., Moreira, A.L., Chen, Y., Wu, M., Stirling, D., & Kaplan, G. (1996). Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Molecular Medicine, 2, 506-515.
14. Dearden, C. (2008). Disease-specific complications of chronic lymphocytic leukemia. Retrieved from http://asheducationbook.hematologylibrary.org/cgi/reprint/2008/1/450
15. Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., Multiple Myeloma (010) Study Investigators. (2007). Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123-2132. doi: 10.1056/NEJMoa070594
16. Eichhorst, B.F., Busch, R., Hopfinger, G., Pasold, R., Hensel, M., Steinbrecher, C., German CLL Study Group. (2006). Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 107, 885-891. doi: 10.1182/blood-2005-06-2395
17. Ferrajoli, A., Lee, B.N., Schlette, E.J., O'Brien, S.M., Gao, H., Wen, S., Keating, M.J. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 111, 5291-5297. doi: 10.1182/blood-2007-12-130120
18. Flinn, I.W., Neuberg, D.S., Grever, M.R., Dewald, G.W., Bennett, J.M., Paietta, E.M., Tallman, M.S. (2007). Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup trial E2997. Journal of Clinical Oncology, 25, 793-798. doi: 10.1200/JCO.2006.08.0762
19. Giagounidis, A., Fenaux, P., Mufti, G.J., Muus, P., Platzbecker, U., Sanz, G., Wells, R.A. (2008). Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Annals of Hematology, 87, 345-352. doi: 10.1007/s00277-008-0449-0
20. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Internal Workshop on Chronic Lymphocytic Leukemia. (2008). Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia. Blood, 111, 5446-5456.
21. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M.J. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59, 225-249. doi: 10.3322/caac.20006
22. Keating, M.J., O'Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Kantarjian, H. (2005). Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4079-4088. doi: 10.1200/JCO.2005.12.051
23. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Myelodysplastic Syndrome-003 Study Investigators. (2006). Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine, 355, 1456-1465. doi: 10.1056/NEJMoa061292
24. Miller, K.C., Padmanabhan, S., Dimicelli, L., Depaolo, D., Landrigan, B., Yu, J.Chanan-Khan, A. (2006). Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leukemia and Lymphoma, 47, 2339-2343. doi: 10.1080/10428190600799631
25. Muller, G.W., Chen, R., Huang, S.Y., Corral, L.G., Wong, L.M., Patterson, R.T., Stirling, D.I. (1999). Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production. Bioorganic and Medicinal Chemistry Letters, 9, 1625-1630.
26. National Comprehensive Cancer Network. (2008). NCCN Clinical Practice Guidelines in Oncology™: Non-Hodgkin's lymphoma [v.1.2008]. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
27. National Comprehensive Cancer Network. (2009). NCCN Clinical Practice Guidelines in Oncology™: Venous thromboembolic disease [v.1.2009]. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
28. Palumbo, A., Rajkumar, S.V., Dimopoulos, M.A., Richardson, P.G., San Miguel, J., Barlogie, B., International Myeloma Working Group. (2008). Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 22, 414-423. doi: 10.1038/sj.leu.2405062
29. Perkins, J.G., Flynn, J.M., Howard, R.S., & Byrd, J.C. (2002). Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: Implications for clinical trials in this patient population. Cancer, 94, 2033-2039. doi: 10.1002/cncr.0680
30. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Schiffer, C.A. (2000). Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1750-1757. doi: 10.1056/NEJM200012143432402
31. Redaelli, A., Laskin, B.L., Stephens, J.M., Botteman, M.F., & Pashos, C.L. (2004). The clinical and epidemiological burden of chronic lymphocytic leukaemia. European Journal of Cancer Care, 13, 279-287. doi: 10.1111/j.1365-2354.2004.00489.x
32. Robak, T., Moiseev, S.I., Dmoszynska, A., Solal-Céligny, P., Warzocha, K., Loscertales, J., Wenger, M.K. (2008). Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression-free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone [Abstract 1]. Retrieved from http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;112/11/lba-1
33. Rome, S., Doss, D., Miller, K., Westphal, J., & IMF Nurse Leadership Board. (2008). Thromboembolic events associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 21-28. doi: 10.1188/08.CJON.S1.21-27
34. Sher, T., Miller, K., Patel, M., Whitworth, A., Musial, L., Lawrence, D., Chanan-Khan, A. (2009). Lenalidomide associated tumor flare reaction correlates with clinical response in patients with relapsed or refractory B-cell chronic lymphocytic leukemia [Abstract 0928]. Haematologica, 94(2, Suppl.), 373.
35. Sturm, I., Bosanquet, A.G., Hermann, S., Güner, D., Dörken, B., & Daniel, P.T. (2003). Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death and Differentiation, 10, 477-484.
36. Tam, C.S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.A., Keating, M.J. (2008). Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood, 112, 975-980. doi: 10.1182/blood-2008-02-140582
37. Tam, C.S., Wolf, M.M., Januszewicz, E.H., Grigg, A.P., Prince, H.M., Westerman, D., & Seymour, J.F. (2004). A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer, 101, 2042-2049. doi: 10.1002/cncr.20615
38. U.S. Food and Drug Administration. (2005). FDA approves new treatment for myelodysplastic syndrome (MDS). Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108546.htm
39. U.S. Food and Drug Administration. (2006). FDA approves lenalidomide oral capsules (Revlimid) for use in combination with dexamethasone in patients with multiple myeloma. Retrieved from http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm095626.htm
40. U.S. Food and Drug Administration. (2009). FDA approves new treatment for chronic lymphocytic leukemia. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187966.htm
41. Wendtner, C.M., Mahadevan, D., Coutré, S., Hillmen, P., Stilgenbauer, S., Frankfurt, O., Chanan-Khan, A. (2009). A phase I dose-escalation of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia [Abstract 0924]. Haematologica, 94(2, Suppl.), 371.
42. Wierda, W., O'Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Keating, M. (2005). Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4070-4078. doi: 10.1200/JCO.2005.12.516